

Three New Weight Loss Drugs: What's the Scoop?
Posted on Aug 16th 2010 11:00AM by Jonny Bowden
jupiterimages
The drugs aren't on the market yet; but some preliminary info is leaking out, and my colleague at the Huffington Post, Dr. David Katz, recently spilled the beans.
The first thing to know is that the FDA typically asks a blue-ribbon advisory panel to make recommendations on a drug, which is exactly what it did here. Regarding Qnexa, the panel voted a big thumbs-down. Qnexa combines two drugs: phentermine (remember fen-phen?), which is an amphetamine (upper), and an anticonvulsant called topiramate. Apparently one of the known side effects is loss of memory and the ability to concentrate. According to Katz, the FDA is likely to take the advice of the panel and nix this one.
Oh, well. One down, two to go. We haven't gotten much news on Contrave. Like Qnexa, it combines two other drugs: an antidepressant (bupropion) and a drug used for addiction treatment (naltrexone). Naltrexone is an opioid antagonist, which means it blocks the feel-good effects of opiates in the brain. According to Katz, preliminary data indicates Contrave is a little less effective than Qnexa. There seems to be somewhat fewer side effects; but one of them is nausea, and it's not uncommon. Good luck with that one.
Over the next year, the placebo group continued to receive placebos (inert substances), but the lorcaserin group were randomly divided in two sections, with half continuing on the drug and the other half taking a placebo. At the end of year two, the researchers again weighed the subjects to see how much of their first year's weight loss was maintained.
However, this is just one study, and the weight loss did not come without a cost. "Among the most frequent adverse events reported with lorcaserin were headaches, dizziness and nausea," reported the researchers.
Jonny Bowden, author, nutritionist and weight loss coach, cuts through all the misconceptions about diet and fitness to help you transform your body, your health and your life. Visit his website to learn more.












